Foreword
As we look ahead to 2025, the pharmaceutical industry is poised for transformation once again. The increasing integration of AI across all facets of the industry is set to revolutionize drug discovery, development, and commercialization, and the pharma industry must be ready to maximize the opportunities it can bring. The industry must also navigate the very tangible landscape of geopolitical risk. Regional instability along with new regulation could disrupt supply chains and impact global operations, necessitating robust risk management strategies.
With global elections now in the 2024 rearview mirror, can the pharma and medtech markets turn toward stable growth that has stagnated marquee M&A in 2024? Therapy areas such as cancer and obesity are driving this growth. Advances in oncology are particularly noteworthy, with innovative treatments offering new hope for patients through radiopharmaceuticals, combinations, and neoadjuvant therapies. The focus on obesity is intensifying, and pharma is investing in the clinic to find new ways of tackling this age-old problem. Expect to see more study results and patient options launched in 2025.
This eBook dives into the key trends and challenges shaping the year ahead, from geopolitical uncertainties to cutting-edge innovation in AI, oncology, and weight-loss therapies. It is part of In Vivo’s comprehensive Outlook 2025 report, offering critical insights into the forces that will define pharma and medtech’s road ahead.
Access the full eBook today!
